Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced an upcoming virtual fireside chat. CEO Marcio Souza will participate in a discussion with TD Cowen's Biotechnology Analyst Ritu Baral on September 2, 2025, at 10:00 AM EST.
The discussion will focus on Praxis' recent presentations at the 36th International Epilepsy Consortium (IEC). The company specializes in developing treatments for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines (NASDAQ: PRAX), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per i disturbi del sistema nervoso centrale, ha annunciato un prossimo incontro virtuale in stile "fireside chat". L'amministratore delegato Marcio Souza parteciperà a una discussione con Ritu Baral, analista di biotecnologie di TD Cowen il 2 settembre 2025 alle 10:00 EST.
Il confronto verterà sulle recenti presentazioni di Praxis al 36° International Epilepsy Consortium (IEC). L'azienda è specializzata nello sviluppo di trattamenti per disturbi del sistema nervoso centrale caratterizzati da uno squilibrio tra eccitazione e inibizione neuronale.
Praxis Precision Medicines (NASDAQ: PRAX), una compañía biofarmacéutica en fase clínica centrada en el desarrollo de terapias para trastornos del sistema nervioso central, ha anunciado una próxima charla virtual tipo "fireside chat". El director ejecutivo Marcio Souza participará en una conversación con Ritu Baral, analista de biotecnología de TD Cowen el 2 de septiembre de 2025 a las 10:00 AM EST.
La discusión se centrará en las presentaciones recientes de Praxis en el 36.º International Epilepsy Consortium (IEC). La compañía se especializa en desarrollar tratamientos para trastornos del sistema nervioso central caracterizados por un desequilibrio entre excitación e inhibición neuronal.
Praxis Precision Medicines (NASDAQ: PRAX)는 중추신경계(CNS) 장애 치료제 개발에 주력하는 임상 단계 바이오제약사로, 곧 가상 파이어사이드 채팅을 개최한다고 발표했습니다. 최고경영자 Marcio Souza가 TD Cowen의 생명공학 애널리스트 Ritu Baral과 2025년 9월 2일 오전 10:00(동부 표준시)에 대담에 참여합니다.
이번 대담은 제36회 International Epilepsy Consortium(IEC)에서의 Praxis 최근 발표를 중심으로 진행됩니다. 이 회사는 흥분과 억제의 불균형으로 특징지어지는 신경계 장애 치료 개발을 전문으로 합니다.
Praxis Precision Medicines (NASDAQ: PRAX), une société biopharmaceutique en phase clinique dédiée au développement de thérapies pour les troubles du système nerveux central, a annoncé une prochaine discussion virtuelle de type "fireside chat". Le directeur général Marcio Souza participera à un échange avec Ritu Baral, analyste en biotechnologie chez TD Cowen le 2 septembre 2025 à 10h00 EST.
La discussion portera sur les récentes présentations de Praxis au 36e International Epilepsy Consortium (IEC). L'entreprise est spécialisée dans le développement de traitements pour les troubles du système nerveux central caractérisés par un déséquilibre entre excitation et inhibition neuronales.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in klinischer Phase mit Schwerpunkt auf der Entwicklung von Therapien für Erkrankungen des zentralen Nervensystems, hat ein bevorstehendes virtuelles "Fireside Chat" angekündigt. CEO Marcio Souza wird am 2. September 2025 um 10:00 Uhr EST an einem Gespräch mit Ritu Baral, Biotechnologie-Analystin bei TD Cowen, teilnehmen.
Die Diskussion wird sich auf Praxiss jüngste Präsentationen beim 36. International Epilepsy Consortium (IEC) konzentrieren. Das Unternehmen spezialisiert sich auf die Entwicklung von Behandlungen für Erkrankungen des zentralen Nervensystems, die durch ein Ungleichgewicht von neuronaler Erregung und Hemmung gekennzeichnet sind.
- None.
- None.
BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Ritu Baral, Biotechnology Analyst, TD Cowen on September 2, 2025 at 10:00amEST to discuss content shared by Praxis at the 36th International Epilepsy Consortium (IEC).
The registration link for the fireside chat can be found here.
The overview of Praxis’ posters and presentation at the IEC event can be found here.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
When is Praxis Precision Medicines (PRAX) fireside chat scheduled for September 2025?
What will be discussed during the PRAX fireside chat with TD Cowen?
Who is hosting the September 2025 fireside chat for Praxis Precision Medicines?
What type of therapies is Praxis Precision Medicines (PRAX) developing?
